Authorized purpose: Study-level triage and prioritization notification for suspected mass effect on non-contrast brain CT in patients aged 22 years and older; not a stand-alone decision or rule-out tool.
Clinical role
Parallel case-level mass-effect notification and worklist prioritization without directing attention to a specific image region.
Images and patients
CT/CTA · Brain/head
Key limitation
Keep in mind: Results are not for stand-alone clinical decision-making, ruling out a finding, or precluding clinical assessment of CTB studies; the device only identifies mass effect and the clinician remains responsible for interpreting the full study.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Study-level triage and prioritization notification for suspected mass effect on non-contrast brain CT in patients aged 22 years and older; not a stand-alone decision or rule-out tool.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain/head Input: DICOM-compliant non-contrast brain CT studies from patients aged 22 years or older.
Who uses it?Intended users: Trained clinicians qualified within their scope of practice to interpret brain CT studies.
What does the software produce?Output: A study-level notification of suspected mass effect delivered to the order and imaging management system for worklist prioritization or triage; no image-region marking or directed attention is provided.
What is its most important limitation?Key limitation: Results are not for stand-alone clinical decision-making, ruling out a finding, or precluding clinical assessment of CTB studies; the device only identifies mass effect and the clinician remains responsible for interpreting the full study.
Clinical takeaway. Clinical role: Study-level triage and prioritization notification for suspected mass effect on non-contrast brain CT in patients aged 22 years and older; not a stand-alone decision or rule-out tool.
Evidence takeaway. Evidence from the reviewed source record: FDA packet: standalone evaluation used independent cohorts of 626 cases at slice thickness at most 1.5 mm (493 positive, 133 negative) and 762 cases above 1.5 mm through 5.0 mm (594 positive, 168 negative), collected from 5 U.S. hospital-network sites. Two ABR-certified, protocol-trained neuroradiologists established consensus with a third for disagreement. Mass-effect sensitivity/specificity were, respectively, 97.0%/88.7% and 96.6%/89.5% at the two <=1.5 mm operating points, and 96.8%/89.3% and 95.3%/92.9% at the two >1.5 mm to <=5.0 mm operating points. A separate n=277 positive-case triage bench study reported turnaround time 81.6 seconds (95% CI 80.3-82.9).
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Study-level triage and prioritization notification for suspected mass effect on non-contrast brain CT in patients aged 22 years and older; not a stand-alone decision or rule-out tool.
A study-level notification of suspected mass effect delivered to the order and imaging management system for worklist prioritization or triage; no image-region marking or directed attention is provided.
Results are not for stand-alone clinical decision-making, ruling out a finding, or precluding clinical assessment of CTB studies; the device only identifies mass effect and the clinician remains responsible for interpreting the full study.
FDA packet: standalone evaluation used independent cohorts of 626 cases at slice thickness at most 1.5 mm (493 positive, 133 negative) and 762 cases above 1.5 mm through 5.0 mm (594 positive, 168 negative), collected from 5 U.S. hospital-network sites. Two ABR-certified, protocol-trained neuroradiologists established consensus with a third for disagreement. Mass-effect sensitivity/specificity were, respectively, 97.0%/88.7% and 96.6%/89.5% at the two <=1.5 mm operating points, and 96.8%/89.3% and 95.3%/92.9% at the two >1.5 mm to <=5.0 mm operating points. A separate n=277 positive-case triage bench study reported turnaround time 81.6 seconds (95% CI 80.3-82.9).
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet: standalone evaluation used independent cohorts of 626 cases at slice thickness at most 1.5 mm (493 positive, 133 negative) and 762 cases above 1.5 mm through 5.0 mm (594 positive, 168 negative), collected from 5 U.S. hospital-network sites. Two ABR-certified, protocol-trained neuroradiologists established consensus with a third for disagreement. Mass-effect sensitivity/specificity were, respectively, 97.0%/88.7% and 96.6%/89.5% at the two <=1.5 mm operating points, and 96.8%/89.3% and 95.3%/92.9% at the two >1.5 mm to <=5.0 mm operating points. A separate n=277 positive-case triage bench study reported turnaround time 81.6 seconds (95% CI 80.3-82.9).
Standalone Mass Effect endpoints: slice thickness <=1.5 mm, operating point 0.160195 = 97.0% (95% CI 95.3%-98.4%) and operating point 0.221484 = 96.6% (94.9%-98.2%); slice thickness >1.5 mm and <=5.0 mm, operating point 0.120944 = 96.8% (95.3%-98.1%) and operating point 0.160195 = 95.3% (93.6%-97.0%).
FDA source
Exact FDA submission
Checked 2026-09-09
These are separate slice-thickness and operating-point mass-effect sensitivity endpoints; triage turnaround time is not accuracy.
Standalone Mass Effect endpoints: slice thickness <=1.5 mm, operating point 0.160195 = 88.7% (95% CI 83.5%-94.0%) and operating point 0.221484 = 89.5% (84.2%-94.0%); slice thickness >1.5 mm and <=5.0 mm, operating point 0.120944 = 89.3% (84.5%-93.5%) and operating point 0.160195 = 92.9% (88.7%-96.4%).
FDA source
Exact FDA submission
Checked 2026-09-09
These are separate slice-thickness and operating-point mass-effect specificity endpoints; do not collapse them into one unqualified value.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Harrison.ai Comprehensive Care (CTB - mass effect) regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested version3.3+
Samplen=1388
IndependenceIndependence not established
K231384
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231384. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM-compliant non-contrast brain CT studies from patients aged 22 years or older.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet describes interfaces with image and order management systems such as PACS/RIS for non-contrast brain CT input and worklist notification output; the device does not lower a study's existing worklist priority, and exact local interfaces/versions are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: A study-level notification of suspected mass effect delivered to the order and imaging management system for worklist prioritization or triage; no image-region marking or directed attention is provided.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A study-level notification of suspected mass effect delivered to the order and imaging management system for worklist prioritization or triage; no image-region marking or directed attention is provided.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA packet describes interfaces with image and order management systems such as PACS/RIS for non-contrast brain CT input and worklist notification output; the device does not lower a study's existing worklist priority, and exact local interfaces/versions are not established.
Harrison.ai's Data Privacy FAQs (issued 2025-09-25) state a compliance baseline aligned with the GDPR and the Australian Privacy Act; that medical image data processed by its solutions is encrypted and pseudonymised or de-identified with measures to minimise re-identification risk; that customer patient images are not collected to train AI models; and that technical, organisational and administrative safeguards protect personal data. Vendor statement; no certification or test report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the FDA applicant is Annalise-AI Pty Ltd; Harrison.ai's own Annalise Enterprise page (2023-08-09, harrison.ai/annalise-enterprise/) states Annalise.ai is now Harrison-AI Medical Pty Ltd, an entity the Harrison.ai privacy notice lists in Section 14, and annalise.ai/privacy-policy redirects to that notice. The FAQ names Harrison.ai. Company-level statement; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Annalise Enterprise CTB Triage Trauma; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K231384 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Case-level prioritization and passive notification for adult non-contrast head CT studies with features suggestive of acute intracranial hemorrhage (ICH); not a stand-alone diagnostic or rule-out tool.
Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.